MedTrace Logo

Dengue Vaccine Strategy in Children Aged 9 to 17 Years in the French Caribbean

NCT04839757 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 590

Last updated 2025-02-21

No results posted yet for this study

Summary

Dengue fever, an arbovirus transmitted by the Aedes mosquito, is a public health problem in all tropical and subtropical regions of the world. There is currently no antiviral treatment and vector control has shown its limits. The 2018 European marketing authorization of the tetravalent chimeric yellow fever / dengue vaccine (Dengvaxia®) is a major step forward in the fight against the disease. Dengvaxia® is indicated for the prevention of dengue due to serotypes DENV 1-4 in subjects aged 9 to 45 years with a history of infection with the dengue virus and living in endemic areas (seroprevalence of at least 70% in the target population).

Dengue seroprevalence data in the French Caribbean territories of Martinique and Guadeloupe dates back to 2011 and concerns only adult blood donors aged 18 to 70 years. To date, no data exists for individuals aged 9 to 17 years in the region.

In order to implement an optimal vaccine introduction strategy for these territories, the main aim of the DengueSEA study is to estimate the seroprevalence of the Dengue viruses (DENV 1-4) in 9-17 year olds giving a blood sample as part of care in hospital departments of the French Caribbean islands of Martinique and Guadeloupe.

Conditions

Sponsors & Collaborators

  • Ecole des Hautes Etudes en Santé Publique

    collaborator OTHER

  • University Hospital Center of Guadeloupe

    collaborator UNKNOWN

  • Observatoire Regional de la Sante Provence-Alpes-Côte d'Azur

    collaborator OTHER

  • Modélisation Mathématique des Maladies Infectieuses UMR 2000, Institut Pasteur

    collaborator UNKNOWN

  • Institut de Recherche en Santé Publique, France

    collaborator OTHER

  • Aix Marseille Université

    collaborator OTHER

  • University Hospital Center of Martinique

    lead OTHER

Principal Investigators

  • Andre CABIE · Martinique University Hospital Center

Eligibility

Min Age
9 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-03
Primary Completion
2025-12-31
Completion
2026-02-28

Countries

  • Martinique

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04839757 on ClinicalTrials.gov